The association of matrix metalloproteinases (MMPs)-enzymes that disrupt the body's normal repair functions-with several diseases, including growing and invasive tumors, holds the tantalizing promise that their inhibiton might have therapeutic value. In Matrix Metalloproteinase Inhibitors in Cancer Therapy, cutting-edge investigators review the current status of the entire field, from the biology of MMPs through the current clinical studies. The authors include many leading scientists from pharmaceutical companies who present all the latest concepts and results on the preferred design strategies for MMP inhibitors, their molecular mechanisms, and their substrates. In addition, they fully describe their company's research effort on specific MMP inhibitors, detailing vanguard design strategies, their in vitro activity, the outcome of animal model studies and, where available, their toxicology, safety, and efficacy in human clinical trials. Comprehensive and state-of-the-art, Matrix Metalloproteinase Inhibitors offers basic and clinical investigators alike a richly informative summary of all the latest research on these powerful new drugs, and their high promise as emerging cancer therapeutics.

Klappentext

Cutting-edge investigators review the current status of the entire field, from the biology of MMPs through the current clinical studies. The authors include many leading scientists from pharmaceutical companies who present all the latest concepts and results on the preferred design strategies for MMP inhibitors, their molecular mechanisms, and their substrates. In addition, they fully describe their personal research on specific MMP inhibitors, detailing vanguard design strategies, their in vitro activity, the outcome of animal model studies and, where available, their toxicology, safety, efficacy in human clinical trials.
Comprehensive and state-of-the-art, Matrix Metalloproteinase Inhibitors in Cancer Therapy offers basic and clinical investigators alike a richly informative summary of all the latest research on these powerful new drugs, and their high promise as emerging cancer therapeutics.

Inhalt

Biology and Regulation of the Matrix Metalloproteinases, Mark D. Sternlicht, Lisa M. Coussens, Thiennu H. Vu, and Zena Werb. Substrate Specificity of MMPs, Hideaki Nagase. The Tissue Inhibitors of Metalloproteinases (TIMPs): Biology and Regulation, Dylan R. Edwards. Matrix Metalloproteinases in Cancer, Barbara Fingleton and Lynn M. Matrisian. Hydroxamic Acid Matrix Metalloproteinase Inhibitors, Peter D. Brown, Alan H. Davidson, Alan H. Drummond, Andrew Gearing, and Mark Whittaker. Prinomastat: A Potent and Selective Matrix Metalloproteinase Inhibitor-Preclinical and Clinical Development for Oncology, David R. Shalinsky, Bhasker Shetty, Yazdi Pithavala, Steve Bender, Anthony Neri, Stephanie Webber, Krzysztof Appelt, and Mary Collier. A Potent Nonpeptidic Matrix Metalloproteinase Inhibitor: Discovery of BAY 12-9566, George Clemens, Barbara Hibner, Rachel Humphrey, Harold Kluender, and Scott Wilhelm. D1927 and D2163: Novel Mercaptoamide Inhibitors of Matrix Metalloproteinases, A.D. Baxter, J.B. Bird, R. Bannister, R. Bhogal, D.T. Manallack, R.W. Watson, D.A. Owen, J. Montana, J. Henshilwood, and Robert C. Jackson. Research on MMP Inhibitors with Unusual Scaffolds, Frank Grams, Hans Brandstetter, Richard A. Engh, Dagmar Glitz, Hans-Willi Krell, Valeria Livi, Ernesto Menta, Luis Moroder, J. Constanze D. Müller, Erich Graf v. Roedern, and Gerd Zimmerman. Matrix Metalloproteinase Inhibitors: Therapeutic Applications Outside of Oncology, Michael R. Niesman. Index.